Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Core Insights - Rigel Pharmaceuticals is considered undervalued due to its recent acquisition of a lung cancer targeted therapy and the growth of its IDH1 inhibitor [1] Company Analysis - The company has a focus on developing therapies for cancer, particularly lung cancer, which is a significant area of interest in the biotech sector [1] - The analyst has a strong background in biochemistry and experience in analyzing clinical trials, indicating a deep understanding of the scientific aspects of the company's products [1]